Neuropace/NPCE

$17.00

0.29%
-
1D1W1MYTD1YMAX

About Neuropace

NeuroPace, Inc. is a commercial-stage medical device company. The Company is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s differentiated RNS System is a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. The Company is developing its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. RNS System is a device that records brain activity data and allows clinicians to monitor patients. RNS System monitors the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorder.

Ticker

NPCE

Sector

Tervishoid

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Frank Fischer

Employees

167

Headquarters

Mountain view, United States

Neuropace Metrics

BasicAdvanced
$447.35M
Market cap
-
P/E ratio
-$1.50
EPS
-
Beta
-
Dividend rate

What the Analysts think about Neuropace

Analyst Ratings

Majority rating from 7 analysts.
Buy

Price Targets

Average projection from 7 analysts.
19.35% downside
High $22.00
Low $9.00
$17.00
Current price
$13.71
Average price target

Neuropace Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-43.9% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$16.4M
-0.61%
Net income
$-7.2M
-20.88%
Profit margin
-43.9%
-20.4%

Neuropace Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 31.71%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.45
-$0.41
-$0.36
-$0.28
-
Expected
-$0.50
-$0.46
-$0.47
-$0.41
-$0.32
Surprise
-9.09%
-10.09%
-22.58%
-31.71%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Neuropace stock

Buy or sell Neuropace stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing